IC
Isaac Ciechanover
Chief Business Officer at Cytokinetics
United States
Overview
Isaac Ciechanover is a highly accomplished professional with a diverse background in healthcare, business, and venture capital. Currently serving as the Chief Business Officer at Cytokinetics, he has held leadership roles at prominent companies like Atara Biotherapeutics and Celgene, showcasing his expertise in the biotech industry and successful investments in companies like eGenesis at Series C stage.
Work Experience
Chief Business Officer
2024 - Current
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Raised $1,760,450,000.00 from Royalty Pharma, Deerfield, Federated Kaufmann Fund and Red Abbey Venture Partners.
Partner
2022 - 2023
Qiming Venture Partners is a venture capital firm that offers early-stage healthcare possibilities in highly disruptive platforms.
Partner
2020 - 2022
Polaris Partners is an investment firm that invests in healthcare and biotechnology companies.
CEO
2012 - 2019
Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.
Raised $535,816,156.00 from Adiumentum Capital Management, Redmile Group and EcoR1 Capital.
Partner
2010 - 2012
Executive Director
2004 - 2010
Associate
2002 - 2003